Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Michael D. Wortley net worth and biography

Michael Wortley Biography and Net Worth

Insider of Reata Pharmaceuticals

Michael D. Wortley joined Reata as Chief Legal Officer in April 2015. Prior to joining Reata, Mr. Wortley was an attorney at Vinson & Elkins L.L.P. from 1995 to March 2015, serving in various capacities, including Chief Operating Partner of the firm and Managing Partner of the Dallas office, and, prior to 1995, at Johnson & Wortley, P.C., serving as Chairman of the Board and President.

He currently serves as a member of the board of directors of Pioneer Natural Resources Company, a publicly traded company. Mr. Wortley earned a B.A. in Political Science from Southern Methodist University, a master’s degree in Regional Planning from the University of North Carolina at Chapel Hill and a J.D. from Southern Methodist University School of Law.

What is Michael D. Wortley's net worth?: The estimated net worth of Michael D. Wortley is at least $8.14 million as of May 15th, 2023. Mr. Wortley owns 47,198 shares of Reata Pharmaceuticals stock worth more than $8,135,047 as of April 27th. This net worth estimate does not reflect any other assets that Mr. Wortley may own. Additionally, Mr. Wortley receives an annual salary of $773,060.00 as Insider at Reata Pharmaceuticals. Learn More about Michael D. Wortley's net worth.
How old is Michael D. Wortley?: Mr. Wortley is currently 75 years old. There are 6 older executives and no younger executives at Reata Pharmaceuticals. Learn More on Michael D. Wortley's age.
What is Michael D. Wortley's salary?: As the Insider of Reata Pharmaceuticals, Inc., Mr. Wortley earns $773,060.00 per year. There are 3 executives that earn more than Mr. Wortley. The highest earning executive at Reata Pharmaceuticals is Mr. J. Warren Huff, Chairman, CEO & Sec., who commands a salary of $1,110,000.00 per year. Learn More on Michael D. Wortley's salary.
How do I contact Michael D. Wortley?: The corporate mailing address for Mr. Wortley and other Reata Pharmaceuticals executives is 5320 LEGACY DRIVE, PLANO TX, 75024. Reata Pharmaceuticals can also be reached via phone at (972) 865-2219 and via email at [email protected]. Learn More on Michael D. Wortley's contact information.
Has Michael D. Wortley been buying or selling shares of Reata Pharmaceuticals?: Michael D. Wortley has not been actively trading shares of Reata Pharmaceuticals in the last ninety days. Most recently, Michael D. Wortley sold 894 shares of the business's stock in a transaction on Monday, May 15th. The shares were sold at an average price of $84.81, for a transaction totalling $75,820.14. Following the completion of the sale, the insider now directly owns 47,198 shares of the company's stock, valued at $4,002,862.38. Learn More on Michael D. Wortley's trading history.
Who are Reata Pharmaceuticals' active insiders?: Reata Pharmaceuticals' insider roster includes Bhaskar Anand (CAO), Dawn Bir (Chief Commercial Officer), Elaine Castellanos (CAO), Samina Khan (SVP), Andrea Loewen (SVP), Colin Meyer (Insider), Shamim Ruff (Director), Manmeet Soni (CFO), and Michael Wortley (Insider). Learn More on Reata Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Reata Pharmaceuticals?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 236,092 shares worth more than $31,588,041.37. The most recent insider tranaction occured on September, 14th when SVP Andrea Loewen sold 3,175 shares worth more than $546,195.25. Insiders at Reata Pharmaceuticals own 26.8% of the company. Learn More about insider trades at Reata Pharmaceuticals.
Information on this page was last updated on 9/14/2023.

Michael D. Wortley Insider Trading History at Reata Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/15/2023	Sell	894	$84.81	$75,820.14	47,198
11/11/2020	Sell	51,429	$179.37	$9,224,819.73	51,429

Michael D. Wortley Buying and Selling Activity at Reata Pharmaceuticals

Reata Pharmaceuticals Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Today's Range

Now: $172.36

$172.32

$172.46

50 Day Range

MA: $171.30

$168.70

$172.36

2 Week Range

Now: $172.36

$21.83

$172.46

Volume

1,988,500 shs

Average Volume

1,091,032 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

From Paradigm Press | Ad

Click here to find out that this 8,788% cryptocurrency is.

Michael Wortley Biography and Net Worth

What is Michael D. Wortley's net worth?

How old is Michael D. Wortley?

What is Michael D. Wortley's salary?

How do I contact Michael D. Wortley?

Has Michael D. Wortley been buying or selling shares of Reata Pharmaceuticals?

Who are Reata Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Reata Pharmaceuticals?